Antihypertensive therapy in obese patients with arterial hypertension

Obesity (O) is one of the main risk factors of arterial hypertension (AH). Clinicians face increasing numbers of patients with a combination of AH and O and the problem of correct choice of antihypertensive therapy, which should effectively control blood pressure, provide cardio- and nephroprotection, and be metabolically neutral. At the present, a fixed-dose combined medication is available, which has all the characteristics required - a combination of a non-dihydropyridine calcium antagonist verapamil in its retard form and ail ACE inhibitor trandolapril. This combination could be a medication of choice in patients with AH, O, diabetes mellitus and nephropathy.